Journals / Haydarpaşa Numune Medical Journal / 2019 / Cilt: 59 - Sayı: 4

Comparison of Adenosine Deaminase (ADA) and Cancer Antigen 125 (CA 125) Levels in Epithelial Ovarian Tumors

Pages
309–314
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To validate these clinical data, large-scale studies of epithelial ovarian tumors are needed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: In this study, we aimed to determine serum adenosine deaminase (ADA) and cancer antigen 125 (CA 125) levels in patients with epithelial ovarian tumors.
📊
Key Findings & Data:Methods: A total of 75 patients with 47 malignant and 28 benign epithelial ovarian tumors were included in this case-control study.
💡
Conclusion & Impact:To validate these clinical data, large-scale studies of epithelial ovarian tumors are needed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Introduction: In this study, we aimed to determine serum adenosine deaminase (ADA) and cancer antigen 125 (CA 125) levels in patients with epithelial ovarian tumors. Methods: A total of 75 patients with 47 malignant and 28 benign epithelial ovarian tumors were included in this case-control study. On the morning of the operation, serum CA 125 and ADA levels were determined. Postoperative epithelial ovarian tumor patients were divided into two subgroups as benign and malignant histopathologically. We evaluated whether there was a correlation between tumor levels and serum CA-125 and ADA levels of subgroups and malignant patients. Results: Of 47 patients with malignant epithelial ovarian cancer, 20 of them had an early-stage (stage 1-2) and 27 of them had advanced-stage (stage 3-4) tumors. Serum CA-125 (26.38 vs 44.93, p<0.001) and ADA levels (29.91 vs 42. 82, p≤0.05) were significantly higher in malignant epithelial ovarian tumors than in benign epithelial ovarian tumors. There was no significant correlation between ADA levels. Discussion and Conclusion: This study showed that serum ADA levels in patients with epithelial ovarian cancer could be used as a biomarker in combination with other parameters for predicting malignancy in ovarian cancer. To validate these clinical data, large-scale studies of epithelial ovarian tumors are needed.

🔖

Cite This Article

TAŞ, M., KORUN, Z. E. U., KOÇAK, A., YAVUZ, A., ÖZÇELİK, B., GÜNGÖR, M., ÖNER, G. (2019). Comparison of Adenosine Deaminase (ADA) and Cancer Antigen 125 (CA 125) Levels in Epithelial Ovarian Tumors. Haydarpaşa Numune Medical Journal, Cilt: 59 - Sayı: 4, 309–314. https://ajindex.com/articles/205893

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Goldstein SR. Postmenopausal adnexal cysts: how clinical management has evolved. Am J Obstet Gynecol 1996;175:1498–501. [CrossRef ] 2. Romanidis K, Nagorni EA, Halkia E, Pitiakoudis M. The role of cytoreductive surgery in advanced ovarian cancer: the general surgeon's perspective. J BUON 2014;19:598–604. 3. Van Driel WJ, Lok CA, Verwaal V, Sonke GS. The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer. Curr Treat Options Oncol 2015;16:14. [CrossRef ] 4. Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 2014;134:455–61. [CrossRef ] 5. Armstrong DK, Bundy B, Wenzel L, Helen Q, Huang MS, Baergen R, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:3443. [CrossRef ] 6. Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol 2015;33:937–43. 7. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;9;361:170–7. [CrossRef ] 8. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1–12. [CrossRef ] 9. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA- 125? Am J Obstet Gynecol 2008;199:215–23. [CrossRef ] 10. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA 125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40–6. [CrossRef ] 11. Sullivan JL, Osborne WR, Wedgewood RJ. Adenosine deaminase activity in lymphocytes. Br J Haematol 1977;37:157–8. 12. Pragathi P, Bharath Kumar PV, Amar Kumar P, Ramakanth Reddy M, Sravani V, Neeraja J, et al. Evaluation of serum adenosine deaminase and 5’ -nucleotidase activities as probable markers in ovarian cancer. Indian J Clin Biochem 2005;20:195–7. [CrossRef] 13. Camici M, Tozzi MG, Allegrini S, Del Corso A, Sanfilippo O, Daidone MG, et al.